Human HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein 2088

Additional Information:
accession A0A140T913(HLA-A*02:01)&P61769(B2M)&KLVVVGAGGV|express systemE.coli|product tagC-His-Avi|purity> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC|backgroundKirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.|molecular weightThe protein has a predicted MW of 35.6 kDa (HLA-A*02:01) and 11.9 kDa (B2M) same as Tris-Bis PAGE result.|available size100 g, 500 g|endotoxinLess than 1EU per g by the LAL method.|Human HLA-A*02:01&B2M&KRAS WT (KLVVVGAGGV) Monomer Protein 2088proteinSize and concentration100, 500g and liquidFormLiquidStorage InstructionsValid for 12 months from date of receipt when stored at -80C. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.Storage bufferShipped with dry ice.Purity> 95% as determined by Tris-Bis PAGEtarget relevanceKirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target.Protein namesMajor histocompatibility complex, class I, AGene namesHLA-A,HLA-AProtein familyMHC class I familyMass41449DaTarget Relevance information above includes information from UniProt accession: A0A140T913The UniProt Consortium|